← Back to Clinical Trials
Recruiting NCT06891625

NCT06891625 Movement Performance in Persons With Chronic Back Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06891625
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Chronic Low-back Pain
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-09-01
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
SMTETOLP

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-09-01 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this laboratory-based cross-over randomized controlled study is to study the immediate effects Spinal manipulative therapy (SMT) and exercise therapy (ET) compared to open-label placebo (OLP) on movement performance, gait, active trunk mobility and pain-intensity in persons with chronic non-specific back pain. The main question this study aims to answer is: What are the immediate and measurable effects of SMT and ET on work movements, gait, active trunk mobility and pain-intensity in people with chronic non-specific back pain, compared with and in combination with open-label placebo treatment (OP)? The investigators hypothesize that the participants, after SMT and ET, will perform the lifting task faster, and use more range of motion in most of the joints. They also believe that a greater range of motion is used during gait and that the active ROM in the back is increased, while the pain intensity scores decrease after these interventions. The investigators hypothesize that the control intervention (OLP) could be effective as an add-on intervention, but not as a single intervention. All participants will receive all three interventions SMT, ET and OLP and to study the immediate effects, the participants will be asked: * to lift a box with two different weights * to walk straight forward with and without a cognitive dual task * perform two clinical tests of active range of motion ( * rate the intensity of their pain "right now" * rank the treatment effects of these three treatment methods

Eligibility Criteria

Inclusion Criteria: * Persons who have either experienced continuous or recurring back pain for a period longer than 3 months). Back pain is defined as problems/discomfort from the spine Th1-S1 with associated costovertebral joints and sacroiliac joints, thus including both the lumbar spine and the thoracic spine. The area of pain extends from Th1 to the inferior gluteal fold but does not include the shoulder blades * \>18 years old, * those who can speak and understand Scandinavian or English. Exclusion Criteria: * "red flags" * persons with specific back problems, rheumatic inflammatory joint- and/or back diseases, fractures, diagnosed hip osteoarthritis, fibromyalgia, or neurological co-morbidity.

Contact & Investigator

Central Contact

Wilhelmus JA Grooten, associated professor

✉ Wim.Grooten@ki.se

📞 +46-8-52488861

Frequently Asked Questions

Who can join the NCT06891625 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Low-back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06891625 currently recruiting?

Yes, NCT06891625 is actively recruiting participants. Contact the research team at Wim.Grooten@ki.se for enrollment information.

Where is the NCT06891625 trial being conducted?

This trial is being conducted at Huddinge, Sweden.

Who is sponsoring the NCT06891625 clinical trial?

NCT06891625 is sponsored by Karolinska Institutet. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology